Cowen & Co. analyst Tyler Van Buren initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Outperform rating.
RBC Capital Maintains Sector Perform on Calfrac Well Services, Lowers Price Target to C$6
RBC Capital analyst Keith Mackey maintains Calfrac Well Services (TSX:CFW) with a Sector Perform and lowers the price target from C$6.5 to C$6.